MMR in the treatment of warts

A study in Egypt examined the efficacy and safety of using intralesional MMR vaccine to treat recalcitrant warts

Seventy men and women with multiple recalcitrant extragenital warts took part. Their largest wart was injected with 0.3 intralesional MMR vaccine every two weeks until clearance or until five injections had been given. Participants were followed up monthly for six months.

Of 65 patients completing the study, clearance was observed in 41 (63%), a partial response in 15 (23%) and no response in nine (14%). Only two patients experienced recurrence of the wart.

The researchers concluded that intralesional antigen immunotherapy using the MMR vaccine appears to be effective and safe and is therefore a promising treatment for patients with recalcitrant warts.

Nofal A, Nofal E, Yosef A et al. Int J Dermatol July 28 2014 doi: 10.1111/ijd.12480


Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

MHRA restricts indications for quinolone antibiotics following EU-wide safety review

MHRA restricts indications for quinolone antibiotics following EU-wide safety review

New restrictions and precautions for use have been...

Emollients, Potential Skin Sensitisers as Ingredients

Emollients, Potential Skin Sensitisers as Ingredients

Potential sensitising agents in emollient preparations.

Ophthalmic Preparations, Preservatives and Potential Sensitisers as Ingredients

Ophthalmic Preparations, Preservatives and Potential Sensitisers as Ingredients

Potential sensitising agents in eye drops and ointments.

Anti-Anginal Preparations, Summary by Pharmacological Class

Anti-Anginal Preparations, Summary by Pharmacological Class

Available formulations of anti-anginal drugs.